Jia L.

1. Apply proactive approach, strategic thinking and leadership to bring forward multiple programs from idea to development candidate, including driving target ideation, executing and implementing in vivo evaluation of novel targets in preclinical and translational models. 2. Lead preclinical discovery and in vivo pharmacology efforts to oversee, design and execute studies of discovery research programs in multiple therapeutic areas, including neuromuscular and inflammatory disorders.

1. Drive preclinical discovery and in vivo pharmacology efforts to execute and implement studies of the most advanced programs (DMD and DM1) in multidisciplinary collaborations with establishing a business deal with Vertex 2. Establish electrophysiological research lab in the vivarium to apply clinical standard outcome measures in murine models, including muscle contractile physiology as well as nerve conduction assessments, to execute and implement proof of concept studies of RNA therapeutics in multiple therapeutic areas including neuromuscular and neurological/PNS diseases 3. Lead a new initiative program to develop RNA therapeutics in personalized cardiovascular medicine and drive preclinical in vitro, ex vivo and in vivo pharmacology effort to validate novel therapeutics 4. Review and synthesize scientific literature and competitive intelligence for novel therapeutic targets in multiple therapeutic areas including cardiovascular, neuromuscular, inflammatory and autoimmune diseases 5. Review regulatory reports for IND

Acquired by Merck in Oct 2021 1. Applied proactive approach, strategic thinking and leadership bringing forward cardiovascular program from idea to development candidate, including 1) proposed therapeutic targets in alignment with Acceleron platforms; 2) identified niche indications in accordance with corporate strategies; 3) initiated discovery and pharmacology efforts to screen and validate novel therapeutic targets 2. Facilitated preclinical discovery and in vivo pharmacology efforts to design and implement target validation, proof of concept, target engagement, PK/PD relationships, and mechanism of action studies in multiple murine models of cardiac diseases (Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Diabetic Cardiomyopathy, Chemotherapy Induced Cardiotoxicity, Aging related Heart Failure, HFrEF and HFpEF) 3. Initiated and lead projects with CROs to conduct in vitro and ex vivo proof of concept studies and execute multiomics profiling studies in translational human models 4. Wrote manuscripts for publications in peer-reviewed journals including one 1st author publication in FEBS Letters and prepared slide decks and delivered oral presentations 5. Provided expert scientific support for the strategic plans of filing intellectual property applications

1. Lead neuromuscular program to support 3 clinical trials, phase I study of ACE-2494 in DMD patients, phase II study of ACE-083 in CMT patients, and phase II study of ACE-083 in FSHD patients, including PK studies for clinical dose predictions and establishment of PK/PD relationships 2. Designed and implemented target validation, proof of concept and mechanism of action studies in multiple murine models of neuromuscular diseases (i.e., DMD, FSHD, CMT, ALS, SMA, and Disuse) with accomplishments of 2 seminal publications including one 1st author in Journal of Clinical Investigation. The work had been selected for several oral presentations at leading international conferences 3. Provided expert scientific support for business development activities including due diligence for acquisitions of new assets, such as ASOs 4. Evaluated ASOs in in vitro and in vivo models of DMD, FSHD and CMT

1. Designed and implemented proof of concept, target engagement and mechanism of action studies in multiple murine models of neuromuscular and neurodegenerative diseases (DMD, FSHD, CMT, ALS, SMA, and Disuse) 2. Enabled candidate selection and demonstrated proof of concept in therapeutic validation with a successful IND 3. Prepared data package and wrote regulatory reports for IND 4. Co-inventor of a patent on the treatment of SMA

1. Executed in multidisciplinary collaborations with pharmaceutical industries including Roche (worked proof of concept of Evrysdi/Risdiplam, which is now an FDA approved drug being used to treat spinal muscular atrophy patients), PTC Therapeutics and Acceleron Pharma (worked electrophysiologic biomarker development of ACE031, an investigational drug) 2. Designed and conducted proof of concept studies to assess therapeutic interventions in murine models of neurodegenerative and neuromuscular diseases, including ALS, SMA, DMD, Myotonic dystrophy and Sarcopenia 3. Scientific lead, developing a medical device, electrical impedance myography (EIM), for neuromuscular diseases

• Characterized the temporal alterations of visual responses in single nerve cells produced by efferent neuromodulation using intracellular electrophysiological recording technique

• Assisted for undergraduate courses: 'Introduction to Psychology', 'Brain and Behavior, Behavioral Neuroscience of Sensation and Arousal', and 'Psychology of Consciousness'. • Mentored undergraduates to conduct electrophysiological research in lab.